EDGAR·FLOW

Aligos Therapeutics, Inc. — Form 8-K

Filed November 6, 2026 · analyzed by the 8-K Agent
8-K ▼ Likely negative significance 78/100
What the filing says
Aligos Therapeutics reported Q3 2026 results with cash/investments declining from $77.8M (Dec 2025) to $31.1M (Sept 2026)—a 60% burn in nine months. The company's Phase 2 B-SUPREME study of pevifoscorvir sodium enrolled 245 participants (131 HBeAg+, 114 HBeAg−) with topline data expected late Q3 2027. Cash runway extends only to Q1 2027. Net loss was $21.9M in Q3 2026 vs. $31.5M in Q3 2025; R&D expenses fell to $18.9M from $23.9M year-over-year. Partner Amoytop is funding ALG-170675 Phase 1 studies in China.
Why this rating

Severe cash burn (60% in 9 months) relative to $19.9M market cap is existential risk; Q1 2027 runway imminent. Offset by clinical progress and partnership, but funding urgency is critical.

Tradability signal
SHORT conviction 47/100 · expected -1.69% over 4 hrs

SHORT (drift): bad news keeps sliding after dissemination — our one persistent measured edge. Similar past filings (271 in this cell) moved +1.85% in the called direction over 4 hrs; shrunk for sample size that's a +1.69% edge. Price is down 3.1% since the filing hit EDGAR — the slide has begun. Caution: sub-$5 shorts can be hard to borrow — treat as avoid-longs if no locate. Exit plan: HARD stop 8% against entry — 1.4× this stock's measured hourly volatility, fixed, not trailing (trails test terribly on these names) — time exit 4 hrs. (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it negative)
at our read · unknown
$4.44
+10 min · unknown
$4.44 ▲ 0.00%
+30 min · unknown
$4.44 ▲ 0.00%
+1 hr · unknown
$4.49 ▲ 1.13%
+4 hrs · unknown
$4.25 ▼ 4.19%

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ ALGS · stock on Yahoo Finance ↗

See more from November 6, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.